Platelet Refractoriness: Examining Associated Morbidity and Mortality
Author(s) -
Sijimol Mathew
Publication year - 2021
Publication title -
clinical journal of oncology nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.375
H-Index - 43
eISSN - 1538-067X
pISSN - 1092-1095
DOI - 10.1188/21.cjon.89-92
Subject(s) - medicine , certification , refractory period , board certification , intensive care medicine , platelet , family medicine , medical education , continuing education , continuing medical education , political science , law
Platelet refractoriness is defined as the failure of platelets to show adequate increment after platelet transfusion. Platelets are important to the normal clotting and hemostasis process in the prevention of bleeding. Platelet refractoriness is a significant clinical concern because of resulting hemorrhagic emergencies, increased length of hospital stays, higher inpatient costs, and decreased survival. As part of the healthcare team, oncology nurses play a crucial role in early detection and using evidence-based management strategies for platelet refractoriness to limit the potential for associated morbidity and mortality.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom